Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11048072 | 1.00 | SIGMAR1 (0.44) | SIGMAR1CYP19A1SLC18A3OPRM1OPRD1 | |
| SCHEMBL8777947 | 0.98 | SIGMAR1 (0.42) | SIGMAR1CYP19A1SLC18A3OPRM1OPRD1 | |
| SCHEMBL9432698 | 0.94 | SLC18A3 (0.46) | SIGMAR1CYP19A1SLC18A3OPRM1OPRD1 | |
| SCHEMBL9433185 | 0.89 | CYP19A1 (0.44) | SIGMAR1CYP19A1SLC18A3CCR3 | |
| SCHEMBL11042566 | 0.87 | CTSS (0.47) | OPRM1OPRD1OPRK1 | |
| SCHEMBL18435050 | 0.82 | SIGMAR1 (0.61) | SIGMAR1CYP19A1SLC18A3OPRM1OPRD1 | |
| SCHEMBL8116499 | 0.81 | CYP19A1 (0.47) | SIGMAR1CYP19A1SLC18A3CCR3 | |
| SCHEMBL8111557 | 0.81 | CYP19A1 (0.47) | SIGMAR1CYP19A1SLC18A3CCR3 | |
| SCHEMBL7392307 | 0.80 | SIGMAR1 (0.64) | SIGMAR1SLC18A3 | |
| SCHEMBL5087578 | 0.80 | SIGMAR1 (0.64) | SIGMAR1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1221440-B1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | OTSUKA PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-0877736-B1 | BENZAZEPINE DERIVATIVES WITH VASOPRESSIN AGONISTIC ACTIVITY | OTSUKA PHARMA CO LTD (JP) | 2004-04-21 | — | — | EP | disclosed |
| US-6642223-B2 | A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-0765314-B1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMA CO LTD (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-1221440-A1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | Otsuka Pharmaceutical Company, Limited (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-20020049194-A1 | Benzoheterocyclic derivatives | OGAWA HIDENORI (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6335327-B1 | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6096736-A | Benzazepine derivatives with vasopressin agonistic activity | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| US-6096735-A | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| EP-0877736-A1 | BENZAZEPINE DERIVATIVES WITH VASOPRESSIN AGONISTIC ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997022591-A1 | BENZAZEPINE DERIVATIVES WITH VASOPRESSIN AGONISTIC ACTIVITY | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1997-06-26 | — | — | WO | disclosed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049194-A1 | Benzoheterocyclic derivatives | AVPR2, AVPR1A, AVPR1B | SIGMAR1 566/4885CYP19A1 190/4885SLC18A3 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.